DE69520959T2 - Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung - Google Patents

Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung

Info

Publication number
DE69520959T2
DE69520959T2 DE69520959T DE69520959T DE69520959T2 DE 69520959 T2 DE69520959 T2 DE 69520959T2 DE 69520959 T DE69520959 T DE 69520959T DE 69520959 T DE69520959 T DE 69520959T DE 69520959 T2 DE69520959 T2 DE 69520959T2
Authority
DE
Germany
Prior art keywords
repelling
precursors
derived peptides
complexes
isolated tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69520959T
Other languages
English (en)
Other versions
DE69520959D1 (de
Inventor
J Melief
W Visseren
M Kast
Der Bruggen Pierre Van
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Ludwig Institute for Cancer Research New York
Original Assignee
Universiteit Leiden
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, Ludwig Institute for Cancer Research New York filed Critical Universiteit Leiden
Application granted granted Critical
Publication of DE69520959D1 publication Critical patent/DE69520959D1/de
Publication of DE69520959T2 publication Critical patent/DE69520959T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69520959T 1994-03-24 1995-03-21 Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung Expired - Lifetime DE69520959T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
PCT/US1995/003535 WO1995025530A1 (en) 1994-03-24 1995-03-21 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof

Publications (2)

Publication Number Publication Date
DE69520959D1 DE69520959D1 (de) 2001-06-21
DE69520959T2 true DE69520959T2 (de) 2002-03-28

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69520959T Expired - Lifetime DE69520959T2 (de) 1994-03-24 1995-03-21 Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung

Country Status (17)

Country Link
US (3) US5554724A (de)
EP (1) EP0810870B1 (de)
JP (1) JP3360137B2 (de)
CN (1) CN1149257A (de)
AT (1) ATE201214T1 (de)
AU (1) AU682597B2 (de)
CA (1) CA2186006A1 (de)
DE (1) DE69520959T2 (de)
DK (1) DK0810870T3 (de)
ES (1) ES2158943T3 (de)
FI (1) FI963780A (de)
GR (1) GR3036320T3 (de)
NO (1) NO963918L (de)
NZ (2) NZ329695A (de)
PT (1) PT810870E (de)
WO (1) WO1995025530A1 (de)
ZA (1) ZA952375B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CN1313481C (zh) 1997-06-23 2007-05-02 路德维格癌症研究所 结合hla分子的分离的九肽和十肽及其应用
EP1103561B1 (de) * 1998-07-28 2006-04-19 Green Peptide Co., Ltd. Hla-a2 beschränktes tumorantigen-peptid, das von sart-1 abstammt
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
EP1808180A3 (de) 1999-10-22 2010-12-22 Sanofi Pasteur Limited Modifiziertes GP 100 und Verwendung dafür
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
WO2004094454A2 (en) * 2003-04-18 2004-11-04 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
BR112013023027A2 (pt) 2011-03-07 2016-08-16 Creative Neail Design Inc composições e métodos para esmaltes de unha curáveis por uv
EP2825572B1 (de) 2012-03-15 2022-07-27 ExxonMobil Chemical Patents Inc. Sauerstoff-tailoring von polyethylen
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
DK0810870T3 (da) 2001-07-23
EP0810870A1 (de) 1997-12-10
US6147187A (en) 2000-11-14
NO963918L (no) 1996-11-20
CA2186006A1 (en) 1995-09-28
ES2158943T3 (es) 2001-09-16
FI963780A0 (fi) 1996-09-23
PT810870E (pt) 2001-09-28
NZ283561A (en) 1998-04-27
JP3360137B2 (ja) 2002-12-24
NZ329695A (en) 2000-05-26
ZA952375B (en) 1995-12-15
EP0810870B1 (de) 2001-05-16
WO1995025530A1 (en) 1995-09-28
AU682597B2 (en) 1997-10-09
JPH10502329A (ja) 1998-03-03
CN1149257A (zh) 1997-05-07
NO963918D0 (no) 1996-09-19
FI963780A (fi) 1996-09-23
US6063900A (en) 2000-05-16
DE69520959D1 (de) 2001-06-21
GR3036320T3 (en) 2001-11-30
US5554724A (en) 1996-09-10
ATE201214T1 (de) 2001-06-15
EP0810870A4 (de) 1998-11-25
AU2189395A (en) 1995-10-09

Similar Documents

Publication Publication Date Title
DE69520959D1 (de) Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
ATE447585T1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
ATE403680T1 (de) Herstellung tetravalenter antikörper
DE69333670D1 (de) Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
GB9826143D0 (en) Tumour rejection antigens
ATE207757T1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
NO963917L (no) Isolerte, MAGE-3-avledete peptider som komplekserer med HLA-A2-molekyler, samt anvendelser derav
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
Cinar Development of mutation-specific T-cell receptor gene therapy for treatment of B-cell malignancies
RU98104739A (ru) Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
GR890100333A (en) Antihuman antigen antibodies

Legal Events

Date Code Title Description
8364 No opposition during term of opposition